Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

CEL-SCI CORPORATION
Mes dernières consult.
Most popular
Report
 SummaryNewsCalendarCompanyFinancials 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases.Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS).Multikine is... 
More about the company
Latest news on CEL-SCI CORPORATION
12/12 CEL SCI CORP : Other Events (form 8-K)
12/11 CEL SCI : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
12/11 CEL SCI : 10-k/a - management's discussion and analysis of financial condition a..
12/11 CEL SCI : NEW STORY CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and ..
12/11 CEL SCI : Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
12/07 CEL SCI : NEW STORY CEL-SCI Reports Recent Data Review by the Independent Data M..
12/07 CEL SCI : Reports Recent Data Review By the Independent Data Monitoring Committe..
11/28 CEL SCI : NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series ..
11/28 CEL SCI : Extends the Expiration Date of Series DD and Series EE Warrants Issued..
11/21 CEL SCI : Announces Update on Arbitration against Former Clinical Research Organ..
More news
Sector news : Bio Therapeutic Drugs
04:24p France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
Managers
NameTitle
Geert R. Kersten CEO, CFO, Director & Chief Accounting Officer
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION22
GILEAD SCIENCES3.64%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS94.94%35 831
GENMAB0.85%11 452
BLUEBIRD BIO INC177.39%9 249